Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

GlobeNewswire11-07

BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481696337?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B419Ou6jZpxa6v7S84ly3A--~B/aD0zMDM7dz03NzY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f08e1c143d300882e0487406e3d25554","is_english":true,"pubTime":"2024-11-07 06:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481696337","market":"us","top_or_hot":-1,"title":"Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences","media":"GlobeNewswire","content":"<div>\n<p>BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...</p>\n\n<a href=\"https://finance.yahoo.com/news/praxis-precision-medicines-participate-three-220000737.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Precision Medicines to Participate in Three Upcoming November Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 06:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/praxis-precision-medicines-participate-three-220000737.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...</p>\n\n<a href=\"https://finance.yahoo.com/news/praxis-precision-medicines-participate-three-220000737.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRAX","symbol_name":"Praxis Precision Medicines, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/praxis-precision-medicines-participate-three-220000737.html","article_id":"2481696337","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B419Ou6jZpxa6v7S84ly3A--~B/aD0zMDM7dz03NzY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f08e1c143d300882e0487406e3d25554"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481696337","pubTimestamp":1730930400,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"BOSTON, Nov. 06, 2024  -- Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system  disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024.Praxis management will participate in a fireside chat at the Truist Securities BioPharma Symposium, taking place in the Lotte New York Palace Hotel in New York, NY on November 7, 2024 at 9:40am ET.Praxis management will also be participating in a fireside chat at the Guggenheim Securities Inaugural Healthcare Innovation Conference, taking place at the InterContinental Boston Hotel in Boston, MA on November 11, 2024 at 1:00pm ET. A live webcast of the fireside chat will be available through this link.Praxis management will also be participating in one-on-one meetings at the Jefferies London Healthcare Conference, taking","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRAX":"Praxis Precision Medicines, Inc.","BK4200":"专卖店","ASO":"Academy Sports & Outdoors, Inc.","CNS":"科恩-斯蒂尔斯金融","MDCO":"麦迪逊医药","BK4135":"资产管理与托管银行","BK4561":"索罗斯持仓","BK4139":"生物科技"},"translate_title":"Praxis Precision Medicines将参加即将于11月举行的三场投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASO":1,"CNS":1,"MDCO":1,"PRAX":1},"content_text":"BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024.\n\nPraxis management will participate in a fireside chat at the Truist Securities BioPharma Symposium, taking place in the Lotte New York Palace Hotel in New York, NY on November 7, 2024 at 9:40am ET.\nPraxis management will also be participating in a fireside chat at the Guggenheim Securities Inaugural Healthcare Innovation Conference, taking place at the InterContinental Boston Hotel in Boston, MA on November 11, 2024 at 1:00pm ET. A live webcast of the fireside chat will be available through this link.\nPraxis management will also be participating in one-on-one meetings at the Jefferies London Healthcare Conference, taking place at the Waldorf Hilton Hotel in London, UK on November 20-21, 2024.\n\nThe Company will also be available for one-on-one meetings at the Truist and Guggenheim conferences. Interested investors should contact their respective corporate access representatives to request meetings.\nThe live webcast of Guggenheim fireside chat will also be available through the “Upcoming & Recent Events” page of the Investors + Media section of the company’s website at www.praxismedicines.com. Following this event, a replay will be posted, when available, to Praxis’ website on the “Events and Presentations” page under the investor section of the website for 90 days.\nAbout Praxis  Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.\nCONTACT: Investor Contact: \nPraxis Precision Medicines \ninvestors@praxismedicines.com \n857-702-9452 \n \nMedia Contact:\nDan Ferry\nLife Science Advisors\nDaniel@lifesciadvisors.com\n617-430-7576","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"Important Conferences","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481696337"}